120 related articles for article (PubMed ID: 38303267)
1. [A Case of Pathological Complete Response for MSI-High Locally Advanced Unresectable Transverse Colon Cancer Treated with Nivolumab plus Ipilimumab Combination Therapy].
Nishizawa Y; Kagawa Y; Inoue A; Ozato Y; Kumode A; Ueda Y; Takahashi M; Fukui A; Komatsu H; Hirota M; Miyazaki Y; Tomokuni A; Motoori M; Iwase K; Fujitani K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1968-1970. PubMed ID: 38303267
[TBL] [Abstract][Full Text] [Related]
2. Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report.
Kato M; Sawayama H; Komohara Y; Hisano Y; Nakamura H; Ohuchi M; Ogawa K; Miyamoto Y; Yoshida N; Baba H
Clin J Gastroenterol; 2024 Feb; 17(1):57-64. PubMed ID: 37874527
[TBL] [Abstract][Full Text] [Related]
3. [MSI-high ascending colon cancer treated with second-line ipilimumab plus nivolumab for conversion surgery:a case report].
Kodama T; Nakazawa J; Kawahira M; Hori T; Motoi S; Yanagi M; Hamada N; Sueyoshi K; Tsubouchi H; Ido A
Nihon Shokakibyo Gakkai Zasshi; 2023; 120(3):256-262. PubMed ID: 36908144
[TBL] [Abstract][Full Text] [Related]
4. [Unresectable Esophageal Cancer on the Elderly Woman Which Was Treated Effectively with Ipilimumab plus Nivolumab-A Case Report].
Fujii T; Suzuki T; Yamaguchi S; Shibata Y; Tazuma S; Akimoto S; Sada H; Shimada N; Tazawa H; Onoe T; Sudo T; Shimizu Y; Tashiro H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1691-1693. PubMed ID: 38303175
[TBL] [Abstract][Full Text] [Related]
5. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Pothuri V; Herndon J; Ballentine SJ; Lim KH; Fields RC
Oncologist; 2021 Sep; 26(9):722-726. PubMed ID: 33982365
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review.
Sawayama H; Miyamoto Y; Ogawa K; Ohuchi M; Hisano Y; Kato M; Tubakihara H; Yoshida N; Baba H
Surg Case Rep; 2022 Dec; 8(1):223. PubMed ID: 36574162
[TBL] [Abstract][Full Text] [Related]
9. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy.
Tauber M; Cohen R; Laly P; Josselin L; André T; Mekinian A
Clin Rheumatol; 2019 Feb; 38(2):601-602. PubMed ID: 30456528
[TBL] [Abstract][Full Text] [Related]
10. [A Recurrent Colon Cancer Successfully Treated by Nivolumab plus Ipilimumab with On and Off for Preventing Exacerbation of Skin Disorders].
Fujii T; Hazama S; Fujise Y; Yoshida K; Ikeda A; Kajiyama M; Hashiyada H; Nakamoto K; Fujiwara D; Yamashita A; Suzuki N; Nagano H; Inoue M; Hino K; Okita K
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1107-1110. PubMed ID: 38035846
[TBL] [Abstract][Full Text] [Related]
11. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
12. Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix.
Paterniti TA; Dorr K; Ullah A; White J; Williams H; Ghamande S
Obstet Gynecol; 2021 Nov; 138(5):813-816. PubMed ID: 34619736
[TBL] [Abstract][Full Text] [Related]
13. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.
Matsumoto R; Arigami T; Matsushita D; Okubo K; Tanaka T; Yanagita S; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Ohtsuka T
World J Surg Oncol; 2020 Jul; 18(1):179. PubMed ID: 32693806
[TBL] [Abstract][Full Text] [Related]
14. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
[TBL] [Abstract][Full Text] [Related]
15. [A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab].
Mukai T; Akiyoshi T; Koga R; Arita J; Saiura A; Ikeda A; Nagasue Y; Oikawa Y; Yamakawa K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Suenaga M; Mizunuma N; Shinozaki E; Yamamoto C; Yamaguchi T
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2561-3. PubMed ID: 23235180
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
Kojima T; Kato R; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Nakaigawa N; Sugino Y; Hamamoto S; Ito H; Murakami H; Obara W
Jpn J Clin Oncol; 2022 Nov; 52(11):1345-1352. PubMed ID: 35920793
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Neoadjuvant Chemotherapy with Modified FOLFOXIRI plus Bevacizumab for Transverse Colon Cancer with Invasion of the Gastric Antrum].
Kanto S; Takeji S; Okamura M; Sakikubo M; Tatsumi K; Yasuda S; Kawabe A
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1517-1520. PubMed ID: 33130754
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
